Wafik S. El-Deiry, MD, PhD, FACP’s Post

Identifying proteomic risk factors for cancer using prospective and exome analyses of 1463 circulating proteins and risk of 19 cancers in the UK Biobank. https://lnkd.in/gP3EpZdN

The UK Biobank's availability of protein measurements and whole exome sequence data has enabled new discoveries in cancer research. A recent study investigated 1463 plasma proteins and their associations with 19 cancers and 9 cancer subsites in UK Biobank participants over an average 12-year follow-up. The results identified 618 protein-cancer associations, including some detectable more than seven years before cancer diagnosis. Genetic analyses provided supportive evidence for 29 of these associations, with four showing strong support from long time-to-diagnosis and both cis-pQTL and exGS analyses. The study's findings suggest a possible role of blood proteins in cancer development and may inform future cancer prevention strategies. Read more about this study in the link below. #cancerresearch #UKBiobank #proteomics #genetics

Did you know that only 15% of lifelong smokers develop lung cancer, and a significant number of cases occur in never-smokers? This suggests that inherited genetic factors play a crucial role in the disease. A recent review highlights the importance of germline testing in lung cancer patients, which can: - Identify individuals at risk - Inform tailored therapeutic approaches - Enable successful prevention through genetic counseling and screening The incorporation of next-generation sequencing in clinical practice has led to the identification of cancer-predisposing mutations in a growing number of patients. Let's continue to advance our understanding of lung cancer and improve patient outcomes through personalized medicine! #LungCancer #GermlineTesting #PersonalizedMedicine https://lnkd.in/g5c5uQHQ

The FDA has approved the first blood test, Invitae Common Hereditary Cancers Panel, which can detect hundreds of hereditary cancer-associated DNA variants in 47 genes, aiding in early cancer risk identification. This marks a new regulatory classification, and the FDA has established special controls, requiring high accuracy in reporting genetic variants. The test is especially significant as it can assess multiple genes simultaneously using next-generation sequencing, offering a streamlined testing process for patients with a focus on clinically significant genes like BRCA1, BRCA2, Lynch syndrome genes, CDH1, and STK11. However, potential risks include false positive/negative results and result misinterpretation. #CancerTesting #HereditaryCancer #FDAApproval

Discover the future of precision medicine with our latest white paper showcasing the performance and capabilities of the new Tapestri scMRD AML Multiomics Assay. Learn how: 💡 The assay resolves the clonal architecture, identifying multiple leukemic clones with co-occurring mutations. 💡 Integrating genotype and immunophenotypic further enhances MRD detection by identifying genotype-specific protein expression patterns.   💡 The assay demonstrates a limit of detection of 0.01%, specificity of ≥ 99%, and a false positive rate of ≤ 3 variants per sample. Read the white paper here ➡ https://bit.ly/3rRaKIa #mrd #aml #leukemia #oncology #cancerresearch #singlecell #singlecellanalysis #multiomics

The UK Biobank's extensive data on protein measurements and whole exome sequences is a treasure trove for researchers. This recent study leveraged this resource to uncover potential links between plasma proteins and cancer risk. After analyzing 1463 proteins and their association with 19 different cancers, they've identified 618 potential protein-cancer associations. Notably, 107 of these associations were detectable for cases diagnosed more than seven years post blood draw. This long-term analysis, coupled with genetic approaches like cis-pQTL and exome-wide protein genetic scores, has revealed promising insights. For instance, proteins such as CD74 and TNFRSF1B with non-Hodgkin lymphoma, ADAM8 with leukemia, and SFTPA2 with lung cancer, show potential roles in cancer development. These findings not only advance our understanding of cancer but also highlight the predictive potential of blood proteins, opening new avenues for early detection and prevention strategies p/b University of Oxford, Queen's University Belfast, Keren Papier, Kezia Gaitskell, Trishna Desai, Chibuzor Ogamba, Mahboubeh Parsaeian, Gillian Reeves, Karl Smith Byrne #CancerResearch #Multiomics #UKBiobank https://lnkd.in/gVBA58bx

Microsatellite Instability (MSI) is a genetic phenomenon characterized by the presence of errors or mutations in repetitive DNA sequences called microsatellites. These microsatellites are short sequences of DNA with repeated units of two to six base pairs. In normal, healthy cells, these sequences remain relatively stable in terms of their length and structure over time. However, in cells with MSI, there is a higher likelihood of these microsatellites undergoing changes in the number of repeats. MSI is of significant importance in genetics and medicine for several reasons: 1. **Cancer Risk Assessment:** MSI is commonly associated with certain types of cancer, including colorectal cancer and endometrial cancer. Genetic testing for MSI can help assess an individual's risk of developing these cancers. 2. **Hereditary Conditions:** MSI can be associated with hereditary conditions such as Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer (HNPCC). Identifying MSI through genetic testing can be crucial in diagnosing and managing these hereditary conditions. 3. **Treatment Decisions:** In some cases, MSI status can influence treatment decisions for cancer patients. Some immunotherapies, like checkpoint inhibitors, have been found to be more effective in MSI-high tumors. Identifying MSI can help guide treatment choices. 4. **Early Detection:** Genetic testing for MSI can assist in the early detection and prevention of certain cancers. Screening individuals with a family history of MSI-related cancers can help identify those at higher risk. 5. **Precision Medicine:** Understanding an individual's MSI status is a component of precision medicine, where treatment approaches are tailored to a person's specific genetic makeup. Know more about our range of services here : To Read More: https://lnkd.in/gTw4JG2R Contact Us: https://lnkd.in/duuytdzr www.bioserve.in +91 912 122 9283 bioserve.india@reprocell.com #MSI #MicrosatelliteInstability #GeneticTesting #CancerRisk #PrecisionMedicine #Healthcare #Genomics #CancerResearch #HereditaryConditions #PersonalizedMedicine #bioserve #reprocell #biomarkers

🔬🧬 The American Society of Clinical Oncology (#ASCO) has issued new guidelines on the selection of Germline Genetic Testing Panels for cancer patients. 🌟 The guidelines emphasize the significance of documenting patients' family history of cancer and recommend offering multigene panel germline testing when clinically meaningful variants in more than one gene are suspected. 🔍 Various cancer types have a list of "strongly recommended" genes for testing, tailored to individual and familial cancer history. 💬 It's crucial to discuss germline testing with patients, considering factors such as cost, insurance coverage, and patient demographics that can impact testing accessibility. 🔑 These guidelines are designed to standardize the approach to germline genetic testing in cancer patients, ensuring both clinical relevance and equitable access to testing. #GeneticTesting #CancerResearch #MedicalGuidelines Read more at link below:

🌟 Exciting News from Cambridge! 🌟 EDX Medical is launching a groundbreaking diagnostic tool in the UK to assess patients' risk of developing hereditary cancer. This innovative germline test, available this summer through private healthcare providers and select NHS genetic testing centers, boasts 99% sensitivity and can identify mutations in 70 genes linked to hereditary cancers. 🧬 Why is this important? Mutations in tumors, especially in prostate, breast, and colorectal cancer, can be inherited. This pan-cancer test empowers doctors to detect genetic risks shared by patients and their families, enabling preventive measures and informed clinical decisions for better long-term outcomes. "Testing family members of cancer patients must be a key part of a National Cancer Prevention and Management Strategy," says EDX CEO Mike Hudson. This aligns with ASCO's May 2024 recommendations, emphasizing the need for broader germline testing. Let's take a proactive step toward cancer prevention and management! #Globaldata #HealthcareInnovation #GeneticTesting #CancerPrevention #EDXMedical #CambridgeUK #NHS #ASCO #GermlineTesting #Medicaldevicenetwork 🔗 Learn more about our mission and this cutting-edge technology.